Asieris Pharmaceuticals obtains approval to conduct phase I study of antibacterial drug
Dec. 27, 2023
Asieris Pharmaceuticals Co. Ltd. announced that it has received approval to commence phase I clinical trials in Australia of its novel antibacterial drug, APL-2301 (ASN-1733, MET-102), under development for the treatment of Acinetobacter baumannii infections.